W h hen asked to design therapy for a patient with an inborn error of metabolism, all but the best informed will respond that enzyme replacement is the obvious answer. Indeed, short of genetic engineering, this would be true in the ideal world. Yet, the means by which to accomplish enzyme replacement has remained elusive. The first problem, of course, is where to find the normal enzyme, the "ammunition" with which to fight the therapeutic battle? Enzymes are generally present in normal tissues at concentrations that are appropriate for their host organism, but not in sufficient quantity to be shared. Protein isolation techniques are very far short of 100% efficient, reducing availability still further. Other barriers to be considered are protein stability, immunogenicity if the source is other than human, and appropriate intracellular localization to optimize function(e.g., intralysosomal) and functional halflife in the secondary host organism. Much attention has been focused on treatment of lysosomal storage disorders, based on the concept (somewhat simplistic) that phagocytosis of an exogenous protein might lead to eventual lysosomal accumulation and increased biological activity in its native site. Beyond these problems lie the questions of means of delivery to the appropriate site in the body and cost of the entire process, in additlon to many issues not addressed in this brief editorial.
Notwithstanding all these barriers to success, many attempts have been made at enzyme replacement therapy, beginning in the early 1970s with the infusions of plasma or leukocytes into patients with mucopolysaccharidoses I and II.1 The chief advantage to this quite nonspecific approach was the availability of enzyme without the need for purification. The chief disadvantage was that it did not work! Later in the same decade an interesting attempt at treatment was made using transplanted fibroblasts from culture,2 which also failed. Efforts toward amniotic transplantation treatment of mucopolysaccharidoses were equally unrewarding. slightly more effective with respect to the systemic manifestations, but therapeutic effects on the central nervous system component of many of these diseases remain problematic.
The first major advance in enzyme replacement therapy came about as the consequence of the successful bulk isolation of glucocerebrosidase from human placenta and a technique for molecular modification.5 Whereas the native glycoprotein molecule comprises about 12% carbohydrate, the altered molecule includes only 6% carbohydrate and terminates with mannose residues at the ends of the oligosaccharide chains, which render specific recognition by macrophages. It is these latter cells that are normally replete with glucocerebrosidase; thus, modification of the exogenous molecule leads to its accumulation in precisely the correct location. The subsequent clinical experience in treatment of the nonneuronal form of Gaucher's disease has been encouraging. The major drawback to the treatment is the enormous cost-more than $100,000/year! Bembi and associates initially reported their efforts to treat Niemann-Pick disease Type B (now classified as Is) with amniotic epithelial cell implantation technique in 1992, indicating that the therapeutic results seemed encouraging.6 Their report, included in this issue,7 is a follow-up of the original study and indicates that the technique results in cor-MARCH 1997CLINICAL PEDIATRICS 147 CLINICAL PEDIATRICS 147 MARCH 1997 Roth rection of the platelet dysfunction and of the pubertal growth failure seen in delayed-onset (Type Is) Niemann-Pick disease. Moreover, the authors report increase in leukocyte sphingomyelinase activity, consistent with their earlier observations. Thus, the authors suggest that, as in Gaucher's disease, it may be possible to isolate purified placental sphingomyelinase for corrective therapy. This is unlikely, however, to be as useful in Niemann-Pick disease as it is in Gaucher's, since the latter is unusual among storage disorders in that accumulation of glucocerebroside occurs exclusively within the macrophage.
Indeed, technological advances are now being made in the realm of gene therapy for Niemann-Pick disease. It is currently possible to retrovirally transduce cultured Niemann-Pick cells, which are then able to express sphingomyelinase activity and to reproduce cells that, in turn, also express the enzyme.8 Thus, we are on the verge of somatic cell gene therapy for this disease, a therapeutic modality that supersedes all previous techniques, including the apparently successful one described here.7 It is devoutly to be hoped that trials with Niemann-Pick somatic cell transduction in vivo begin soon, for it is the logical avenue for treatment of this dreadful disease.
